Skip to main content
Clinical Trials/NCT02895659
NCT02895659
Completed
Phase 4

Fluid Management in Patients Undergoing Cardiac Surgery - Effects of an Acetate Versus Lactate Buffered Balanced Infusion Solution on Hemodynamic Stability, a Randomized Controlled Double-blind Trial

Insel Gruppe AG, University Hospital Bern1 site in 1 country150 target enrollmentDecember 1, 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Critical Illness
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
150
Locations
1
Primary Endpoint
Cumulative dose of inopressors (norepinephrine and epinephrine) per kg bodyweight/hour during the perioperative period
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Background: Currently used crystalloid solutes have a variable composition and may therefore influence acid-base status, intra- and extracellular water content and plasma electrolyte compositions and have a major impact on organ function and outcome. Despite continuing evaluation no superiority of one particular type of fluid has been reached so far. To the best of the investigators' knowledge no study in humans has ever assessed whether the type of crystalloid fluid given for fluid resuscitation in patients undergoing cardiac surgery has an impact on hemodynamic stability and cardiac function so far. Nonetheless in the animal model it was shown that the choice of crystalloid fluid may greatly influence cardiac performance

Primary Aim: In this study the investigators want to clarify whether a balanced type acetate-buffered fluid solution in patients undergoing cardiac surgery is associated with better hemodynamic stability and cardiac function than a lactate-buffered crystalloid solute.

Registry
clinicaltrials.gov
Start Date
December 1, 2016
End Date
October 19, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Elective single heart valve replacement
  • Elective double valve replacement
  • Elective single or double valve replacement and coronary artery bypass grafting

Exclusion Criteria

  • Patients unable to give informed consent
  • Patients younger than 18 years of age or older than 80 years
  • Pregnancy or breastfeeding
  • Ejection fraction (EF) of less than 30% preoperatively
  • Preexisting renal insufficiency with a glomerular filtration rate below 30ml/min
  • Patients transferred form the intensive care unit to the operating theater
  • Emergency operation
  • Reoperation
  • Patients planned for fast-track surgery
  • Patients planned for minimal extracorporal circuits

Outcomes

Primary Outcomes

Cumulative dose of inopressors (norepinephrine and epinephrine) per kg bodyweight/hour during the perioperative period

Time Frame: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))

Secondary Outcomes

  • Cumulative dose of inodilators(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))
  • Time on inodilators(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))
  • Cumulative dose of vasodilatators(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))
  • Time on vasodilatators(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))
  • Changes in acid-base status(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))
  • Time on inopressors(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))
  • Total amount of fluid(Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours)))

Study Sites (1)

Loading locations...

Similar Trials